Dr. Pons is CEO of Alexo Therapeutics, a venture-funded Immuno-Oncology company co-founded and funded by venBio. Previously, as Senior Vice-President at Pfizer, he was Chief Scientific Officer and site head of Rinat (Pfizer) from 2007 to 2015, where he was responsible for portfolio delivery from idea to human proof of concept. During his tenure at Pfizer, Dr. Pons also served as Chief Technology Officer for Biotherapeutics, focusing on the evaluation and licensing of new platform technologies, member of Pfizer’s World R&D Leadership Team and member of the Portfolio Strategy Investment committee, the governance body that evaluates Pfizer’s clinical projects and guards the gateway to Phase 3 investment.
Dr. Pons is an inventor of three antibodies in late-stage clinical development (tanezumab, bococizumab and TEV-48125) and has advanced nine additional antibodies into human trials in multiple therapeutic areas. Before Pfizer, Dr. Pons created and led Rinat’s protein engineering group and was a scientist at Chiron. Dr. Pons earned his Ph.D. in Molecular and Cell biology at the Institute of Fundamental Biology, Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.